Sanofi's rash of dealmaking has continued with a $2.5 billion tie-up with Chinese cancer immunotherapy biotech Adagene, focused on developing a new generation of safer antibody-based therapies.

A year and a half after Sanofi swooped in on Johnson & Johnson’s dismantled vaccines unit to pick up an E. coli candidate, the asset has failed its phase 3 trial. A scheduled review by the study ...

Biotech giants Genentech and Sanofi are set to lay off hundreds of ... a decade to wind down production at its South San ...

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp ...

After careful consideration, Sanofi opted to implement SureView Systems’ Immix Command Center software platform as a way to not only easily incorporate information from a multitude of physical ...